Safety of an IV formulation of carbamazepine.
An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100mg of study drug as replacement for 100mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.
Conway
Jeannine M
JM
Experimental and Clinical Pharmacology, University of Minnesota, 5-130 WDH, 308 Harvard St. S.E., Minneapolis, MN 55455, United States. pluha003@umn.edu
White
James R
JR
Birnbaum
Angela K
AK
Eugene Ramsay
R
R
Pennell
Page B
PB
Rarick
John O
JO
Musib
Luna
L
Leppik
Ilo E
IE
Cloyd
James C
JC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D000927:Anticonvulsants; D002220:Carbamazepine